0021-972X/05/$15.00/0
*Printed in U.S.A.*

The Journal of Clinical Endocrinology & Metabolism 90(2):1114–1122
Copyright © 2005 by The Endocrine Society
doi: 10.1210/jc.2004-1572

# Single Injections of Vascular Endothelial Growth Factor Trap Block Ovulation in the Macaque and Produce a Prolonged, Dose-Related Suppression of Ovarian Function

Hamish M. Fraser, Helen Wilson, John S. Rudge, and Stanley J. Wiegand

*Medical Research Council Human Reproductive Sciences Unit (H.M.F., H.W.), Centre for Reproductive Biology, Edinburgh EH16 4SB, United Kingdom; and Regeneron Pharmaceuticals (J.S.R., S.J.W.), Tarrytown, New York 10591*

**Follicular development is associated with intense angiogenesis and increased permeability of blood vessels under the control of locally produced angiogenic factors such as vascular endothelial growth factor (VEGF). The aim of the present study was to evaluate the effects of transient inhibition of VEGF on pituitary-ovarian function in the macaque. Animals were given a single, iv injection of a potent, receptor-based VEGF antagonist, the VEGF Trap. VEGF Trap was given at a dose of 4, 1, or 0.25 mg/kg in the midfollicular phase or at 1.0 mg/kg in the late follicular phase. Controls were treated with vehicle or a control protein, recombinant human Fc (1 mg/kg). Blood samples were collected once daily for 12 d after injection, and three times per week thereafter until normal ovulatory cycles had resumed. The VEGF Trap produced a rapid suppression of estradiol and inhibin B concentrations at all doses tested, followed by a marked and sustained increase in LH and FSH. Ovulation and formation of a functional corpus luteum, as evidenced by increased serum progesterone levels, failed to occur at the anticipated time. Normal ovarian activity resumed when plasma concentrations of unbound VEGF Trap fell below about 1 mg/liter. When treatment was initiated in the midfollicular phase, control macaques ovulated 7.2 ± 0.4 d later, but ovulation was delayed in a dose-dependent manner by VEGF Trap, occurring 23 ± 0.7, 30 ± 1.4, and 43 ± 0.8 d after injection of 0.25, 1, or 4 mg/kg, respectively. Thus, the VEGF Trap exerts a potent, dose-dependent, but reversible inhibitory effect on ovarian function. (*J Clin Endocrinol Metab* 90: 1114–1122, 2005)**

IT IS NOW generally accepted that follicular angiogenesis and vascular permeability are closely regulated by a complex interplay of stimulatory and inhibitory vasoactive factors produced by the theca and granulosa (1). Given the close association between structural and functional vascular remodeling and follicular maturation, it has long been postulated that manipulation of follicular angiogenesis could affect ovarian function (2–4). However, initial pharmacological studies that attempted to establish the link between ovarian angiogenesis and function met with mixed success because they of necessity employed relatively nonspecific compounds whose mechanism of action, and potency, were largely unknown (5–7). Over the last few years, the development of improved reagents targeted to defined angiogenic factors or their receptors has enabled studies that have unequivocally confirmed the importance of angiogenesis in ovarian function, and particularly implicated vascular endothelial growth factor (VEGF)-A and its receptors as key mediators of this process.

In these experiments, the VEGF pathway has been inhibited using antibodies directed against VEGF itself (8, 9), antibodies to the VEGF receptor VEGFR-2/Flk (10, 11), a VEGF receptor tyrosine kinase inhibitor (12), or by decoy VEGF receptors (13, 14). We employed highly potent receptor-based VEGF antagonists. Initial studies in marmosets used a prototypical receptor-based antagonist, VEGF $Trap_{A40}$, which comprised the immunoglobulin domains 1–3 of VEGFR-1 fused to the Fc portion of human IgG. Surprisingly, acute systemic administration during the early luteal phase inhibited not only luteal angiogenesis (15) but also follicular angiogenesis (16). In subsequent studies a successor molecule, VEGF $Trap_{R1R2}$, was employed to evaluate the effects of inhibition of VEGF throughout the follicular phase. These studies confirmed that selective inhibition of VEGF markedly attenuated thecal angiogenesis and restricted follicular growth in the marmoset (17).

The small size of the marmoset restricts the number of blood samples that may be obtained to monitor the concomitant effects of VEGF inhibition on pituitary and ovarian hormones. In contrast, the stump-tailed macaque is an old world primate with a body weight of 12–15 kg and menstrual cycles similar to the human female, whose hormone profiles can be determined by well-established assays from blood samples collected at close intervals. We used this species previously to evaluate the effects of GnRH analogs (18) before initiating clinical investigations in women (*e.g.* Ref. 19). The first objective of the current study was to assess the acute and longer-term effects of a single, iv injection of the VEGF $Trap_{R1R2}$ at the midfollicular phase in the macaque. This phase was selected for detailed study because the follicle that will eventually ovulate is being selected at this time. Our earlier studies in the marmoset suggested that VEGF-mediated angiogenesis is of crucial importance in the selection

**First Published Online November 23, 2004**

Abbreviations: OHSS, Ovarian hyperstimulation syndrome; PCOS, polycystic ovarian syndrome; VEGF, vascular endothelial growth factor.

**JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.**



**Celltrion Exhibit 1033**
**Page 1**

and growth of the dominant follicle and that if VEGF action were effectively abrogated, the follicular cycle could not continue and a new phase of follicular recruitment would have to be initiated. A second objective was to determine the minimal dose of VEGF $Trap_{R1R2}$ that would be required to interrupt follicular development and whether the duration of the subsequent suppression of ovarian function would also be dose related. A third objective was to assess the effects of acute VEGF inhibition during the late follicular phase when the thecal vasculature of the ovulatory follicle is already fully developed.

## Materials and Methods

### *Animals*

Thirteen adult female stump-tailed macaques aged 7–22 yr and weighing 10–16 kg used in the study were captive bred in the United Kingdom or Holland and housed in a unit opened in 1996 and designed with an emphasis on environmental enrichment (20). The animals moved freely from their living rooms via a tunnel to cages for their water supply and sleeping area and collection of blood samples.

Vaginal swabs were taken with a cotton-tipped applicator each morning and the pattern of menstrual bleeding recorded. The animals were trained to enable blood sample collection by femoral venipuncture without anesthesia and with minimal or no restraint. All the animals in the study had regular ovulatory menstrual cycles as determined from menstrual pattern and serum concentrations of estradiol-17$\beta$ and progesterone in blood samples obtained three times per week before treatment. The study was approved by the local Primate Ethical Committee and carried out under a project license granted by the United Kingdom Home Office.

### *Treatments*

Endogenous VEGF was inhibited by administration of VEGF $Trap_{R1R2}$, a recombinant, chimeric protein comprising Ig domain 2 of human VEGF-R1 and Ig domain 3 of human VEGF-R2, expressed in sequence with the human Fc. Compared with earlier versions of receptor-based fusion proteins, the VEGF $Trap_{R1R2}$ exhibits greater affinity for VEGF-A (affinity constant ~1 pM) as well as improved bioavailability and pharmacokinetic properties (21). VEGF $Trap_{R1R2}$ (Regeneron Pharmaceuticals, Inc., Tarrytown, NY) was provided at a concentration of 24.3 mg/ml in 2-ml aliquots in buffer composed of 5 mM phosphate, 5 mM citrate, 100 mM NaCl (pH 6.0), and 0.1% wt/vol Tween 20, with either 20% glycerol or 20% sucrose. Human Fc, for control treatments, was provided at a concentration of 19.7 mg/ml in buffer composed of 40 mM phosphate and 20 mM NaCl (pH 7.4). VEGF Trap vehicle alone also was employed during some control cycles. The compounds were stored at −20 C until required, at which time they were thawed. Any compound remaining was stored at 4 C and used within 2 wk.

In a pilot study in two macaques, a single iv injection of 12.5 mg/kg, VEGF $Trap_{R1R2}$ was found to effectively inhibit ovarian function for more than 40 d. Therefore, in the main study, we elected to investigate the response to 4.0, 1.0, and 0.25 mg/kg (n = 4 per group) administered as a single dose (iv) during the midfollicular phase, d 6–8 of the cycle. Late-follicular-phase administration was studied at the intermediate dose of 1 mg/kg (n = 4). In comparable control cycles, macaques were treated with either 1 mg/kg human Fc (iv) during the mid- (n = 3) or late follicular phase (n = 2) or vehicle administered during the mid- (n = 3) or late follicular phase (n = 3).

After treatment with VEGF $Trap_{R1R2}$, vehicle, or Fc, (d 0), blood samples were collected at 0 and 15 min and 4, 6, and 8 h and then daily for the next 12–14 d. Thereafter, blood samples were collected three times per week until normal ovulatory cycles were reestablished, as evidenced by elevation of progesterone levels consistent with luteal values measured in pretreatment cycles for that macaque. Because of limits in numbers of animals available, five animals received two treatments with VEGF $Trap_{R1R2}$. In addition, one animal had been treated in the pilot study. In this case, antibodies to the VEGF $Trap_{R1R2}$ were detected during the second treatment cycle, and the affected cycle was excluded from further analysis (see *Results*).

Because no differences were noted in the effects of vehicle and Fc administration (neither treatment produced an appreciable affect on ovarian or pituitary hormones), control cycles from both control treatment conditions were combined for statistical analyses.

### *Assays*

Estradiol-17$\beta$ and progesterone were measured by RIAs as described previously (22), detection limits being 30 pM and 0.7 nM, respectively. LH and FSH were measured by RIAs based on recombinant cynomolgus monkey LH and FSH supplied by the National Hormone and Pituitary Program (Dr. A. F. Parlow, National Institute of Diabetes and Digestive and Kidney Diseases). FSH was measured using anticynomolgus FSH with a detection limit of 2 $\mu$g/liter (National Institute of Child Health and Human Development, rec-mo-FSH-RP-1, AFP-6940A), and interassay coefficient of variance of 12%. LH was measured using a rabbit antiserum to cynomolgus LH (AFP342994) used at a final dilution of 1:750,000. Rec-mo LH-RP-1 (AFP-6936H) was used for radioiodination as instructed and results expressed as micrograms per liter of the same preparation. Assay sensitivity was 0.3 $\mu$g/liter and interassay coefficient of variance 11%. Inhibin B was measured throughout the study period in animals in the VEGF Trap treatment groups only. The assay was as described previously (20) and had a detection limit of 10 ng/liter.

VEGF $Trap_{R1R2}$ was measured by an ELISA, using human VEGF 165 to capture and an antibody to the human Fc region as the reporter (21). Capture of the VEGF $Trap_{R1R2}$ by VEGF coated on the microplate requires a vacant VEGF binding site. Consequently, this ELISA specifically detects only VEGF Trap that is not already bound to endogenous VEGF. Serum samples were diluted in assay buffer and run against standards also prepared in assay buffer. Each dilution level was assayed, and those that read on the linear part of the standard curve, in which the samples ran parallel to that of the reference standard, were selected for analysis. If in the initial assay, values were below the limit of detection, samples were reassayed neat and the standards spiked with an equivalent volume of mouse serum. Assay sensitivity was 0.14 $\mu$g/liter, and interassay variation based on low-, medium-, and high-quality controls were less than 10%. Concentration *vs.* time curves were constructed from ELISA-generated VEGF Trap values obtained from individual animals. The pharmacokinetic parameter estimates were determined by fitting the serum concentration *vs.* time profile to a noncompartmental model (WinNonLin, version 2.0, Pharsight Corp., Mountain View, CA).

### *Data analysis and statistics*

The day of ovulation was defined as the day of the LH peak. Peak levels of estradiol were typically noted on the previous day or in some cycles on the same day as the LH peak. In normal cycles, the LH peak was followed within 1 d by a rise in progesterone levels, which were sustained for 2 wk. In pre- and posttreatment cycles in which blood samples were obtained three times per week, gonadotropin and ovarian steroid levels were evaluated to provide a best estimate of the day of ovulation.

Data for ovarian and pituitary hormones as well as VEGF $Trap_{R1R2}$ concentrations for each individual animal were plotted with reference to the day of treatment (d 0). Data around d 0 were also plotted as mean ± SEM values for each treatment group: beyond the point at which daily blood samples were available (after 12–14 d), mean values were obtained by averaging samples taken from all animals at the nearest equivalent times (*e.g.* in a group of four, collections of n = 1 at d 20, n = 2 at d 21, and n = 1 at d 22 were averaged and plotted as n = 4 at d 21).

Data for time to ovulation after treatment and effects of treatment on hormone concentrations were subjected to ANOVA using the Prism program 4 for Macintosh (GraphPad Prism, San Diego, CA) followed by Bonferroni's multiple comparison tests. To determine effects of treatment within an animal, the mean of the three pretreatment values for each hormone was used. The posttreatment period subjected to statistical analysis for each group was based on the observed duration of response to treatment defined as the average period of suppression of estradiol below pretreatment value. The final day of response was the one that preceded three consecutive values above pretreatment value.

According to this definition, average duration of response was 30, 17, and 10 d for the 4, 1, and 0.25 mg/kg doses, respectively. Similar estimates of the duration of response were obtained using suppression of inhibin B as an end point. Area under the curve for progesterone and estradiol peaks was compared for pre- and posttreatment cycles. Differences were considered significant at a level of $P < 0.05$.

## Results

### *Midfollicular phase treatment*

A representative example of the hormone profile for vehicle-treated or Fc-treated control cycles is shown in Fig. 1. After control injections, plasma estradiol levels continued to rise, increasing sharply 4–6 d later, before ovulation. The ovulatory surge in LH/FSH took place 7.2 ± 0.4 d (mean ± SEM) after treatment and was followed by a sustained elevation in plasma progesterone, which reached a plateau 8–12 d post ovulation before falling to follicular phase values around luteal d 14–16. Of the six midfollicular control cycles studied, ovulation was not observed at the anticipated time in one vehicle-treated animal, and this cycle was excluded from further evaluation. This animal had an extended follicular phase of 20 d, but this was distinguished from the response to VEGF Trap treatment in that the delay in ovulation was not accompanied by a suppression of estradiol levels or a prolonged rise in LH and FSH (see below).

The VEGF $Trap_{R1R2}$ was well tolerated at all doses tested. Typical hormonal responses observed after administration of




FIG. 1. Serum concentrations of estradiol (*open circles*), progesterone (P4, *closed circles*) (*left panel*), FSH (*closed squares*), and LH (*open squares*) (*right panel*) in individual macaques injected in the midfollicular phase with either Fc (1 mg/kg, iv) (control) or 0.25, 1, or 4 mg/kg VEGF $Trap_{R1R2}$ iv (*arrow*). Note the suppression of estradiol, failure of ovulatory progesterone rises, and increases in LH and FSH after treatment, followed by dose-related recovery of normal pituitary-ovarian function.

0.25, 1.0, and 4.0 mg/kg of the VEGF $Trap_{R1R2}$ are shown in Fig. 1. Pituitary-ovarian function was clearly altered in every case at each dose tested, and the observed changes in hormonal profiles followed a consistent and distinctive pattern. Treatment with VEGF $Trap_{R1R2}$ not only inhibited the late follicular phase rise in plasma estradiol but also resulted in a rapid decline in estradiol concentrations to early follicular phase levels. Within 2–3 d of injection, a progressive increase in plasma LH and FSH was observed, and the FSH to LH ratio was increased in all animals relative to those normally observed during the preovulatory surge of LH and FSH (Fig. 1).

Comparison of mean data for control and treated cycles is shown in Fig. 2. In the posttreatment period, serum estradiol levels in VEGF Trap-treated cycles were significantly lower than in control cycles for all doses tested ($P < 0.0001$). A sustained reduction of estradiol levels below pretreatment follicular values was observed in the 4 mg/kg group ($P < 0.0001$), in which estradiol levels remained significantly below normal follicular levels between d 6 and 28 post treatment. Conversely, VEGF Trap treatment resulted in a significant stimulatory effect ($P < 0.01$) on LH concentrations at all three dose levels. Serum FSH levels also were significantly higher ($P < 0.0001$) than control cycle values in all three treatment groups. FSH appeared to rise and reach a plateau slightly more rapidly than LH. The rate of the rise in serum gonadotropins appeared unaffected by dose of VEGF Trap, although peak values seen between 15–20 in the higher dose groups may not have been obtained in the 0.25 mg group as a result of the more rapid recovery.

Evaluation of percentage change from pretreatment values during the first 48 h after injection showed that inhibin B concentrations exhibited a more rapid and marked decline than estradiol, being significantly suppressed as early as 8 h (0.25 and 1 mg/kg doses), whereas estradiol was not significantly different from pretreatment value until 24 or 48 h (Fig. 3).

### *Pharmacokinetics and pharmacodynamics*

Mean peak concentrations of free VEGF $Trap_{R1R2}$ measured in the first postinjection blood sample at 15 min were




FIG. 2. Serum concentrations of estradiol, progesterone, LH, and FSH after treatment with vehicle/Fc or 0.25, 1, or 4 mg/kg VEGF $Trap_{R1R2}$ in the midfollicular phase. Values are means ± SEM plotted with reference to the day of injection (d 0). Note the timely rise in estradiol, followed by the preovulatory LH/FSH surge and sustained rise in luteal progesterone levels in controls. VEGF $Trap_{R1R2}$ treatment results in the failure of the characteristic increases in estradiol and progesterone and the induction of a persistent increase in LH and FSH. Note the dose-related duration of response followed by recovery initiated by the rise in estradiol.




FIG. 3. Percentage change from pretreatment values in inhibin B and estradiol after treatment with vehicle/Fc or 0.25, 1, or 4 mg/kg VEGF $Trap_{R1R2}$ in the midfollicular phase. Note the more rapid decline in inhibin B, which was significantly lower by 8 h, whereas estradiol was not significantly suppressed until 24 or 48 h.

10.8, 34, and 140 mg/liter for the 0.25, 1, and 4 mg/kg groups, respectively. The clearance at the different doses ranged from 5.8 to 8.7 ml/d/kg, and the steady-state volume of distribution was approximately 34.8 ml/kg.

The differential duration of suppression in ovarian function observed at each dose of VEGF $Trap_{R1R2}$ was temporally correlated with clearance of unbound VEGF Trap from the circulation. The mean estradiol and inhibin B values for each of the three dose groups are plotted in relation to levels of VEGF Trap in Fig. 4. At each dose, inhibin B was suppressed to the detection limit of the assay, whereas estradiol was maintained around early follicular levels until plasma concentrations of VEGF $Trap_{R1R2}$ fell below approximately 1 mg/liter.

The duration of suppression in ovarian function produced by administration of the VEGF Trap was clearly dose related. The time to the first posttreatment ovulation was significantly longer ($P < 0.001$) in the 4 mg/kg group than either the 1 or 0.25 mg/kg groups, and the 1 mg/kg dose also resulted in a significantly longer ($P < 0.002$) period of suppression than 0.25 mg/kg (Fig. 5).

A single exception to the above pattern was observed in one macaque that received a 4 mg/kg injection. The initial 10-d posttreatment period was associated with hormonal profiles indistinguishable from that of others in this dose group. However, estradiol levels began to increase rapidly around d 11. This uncharacteristically rapid escape from the effect of VEGF inhibition was associated with an early and abrupt fall in serum-free Trap levels to 1.5 mg/liter at d 10, compared with around 20 mg/liter at this time point in the other animals in this group. The sample taken at d 10 from this atypical case was assayed for antibodies to the VEGF $Trap_{R1R2}$ and found to be positive, 6478 mIU/ml. This macaque had been injected with 12.5 mg/kg VEGF Trap $_{R1R2}$ in the pilot study 16 months previously.

*Characteristics of posttreatment recovery of ovarian cycles*

Evaluation of the hormonal profiles on recovery of ovarian function suggested that posttreatment menstrual cycles were characteristically normal in terms of length as well as the pattern and magnitude of pituitary gonadotrophin and ovarian steroid levels. This impression was confirmed by quantitative analyses, which showed that peak preovulatory estradiol levels and area under the curve for progesterone during subsequent luteal phase were not statistically different in the immediate pre- and posttreatment cycles (Table 1).

*Vaginal bleeding*

In control cycles, bleeding was detected during the first week post treatment in one of six cases. Nine of the 12 macaques treated with VEGF $Trap_{R1R2}$ during the midfollicular phase exhibited bleeding during this period, likely reflecting the abrupt and sustained reduction in estradiol levels.

*Late follicular phase treatment*

Where control injections were given during the late follicular phase, serum estradiol levels continued to rise and a distinct LH/FSH surge occurred 1–5 d later, followed by a sustained rise in serum progesterone. In marked contrast, the anticipated preovulatory rise in estradiol and ovulatory progesterone were blocked in all macaques treated with VEGF Trap (1 mg/kg); rather there was a rapid and sustained decrease in plasma estradiol levels (Figs. 6 and 7), which persisted for an average of 19 d in three of the four treated macaques. Treatment was followed within 1 d by a marked increase in LH and FSH secretion (Figs. 6 and 7). In contrast to the midcycle gonadotrophin surge seen in normal and control cycles, the LH/FSH increase produced by administration of VEGF $Trap_{R1R2}$ was characterized by a marked increase in the FSH to LH ratio. In the remaining animal, the suppression in estradiol was maintained for only 8 d, and the duration of the LH/FSH rise was similarly abbreviated.

The peak of unbound VEGF $Trap_{R1R2}$ (39 mg/liter) in the serum, as well as other pharmacokinetic parameters (not shown), closely resembled those observed after midfollicular phase injection of 1 mg/kg VEGF Trap. As was the case for midfollicular phase injections, recovery of ovarian function, as evidenced by an increase in estradiol levels followed by normalization of gonadotrophin levels, occurred only after circulating levels of unbound VEGF $Trap_{R1R2}$ fell below about 1 mg/liter. The more rapid recovery of estradiol secretion observed in one animal was not accompanied by accelerated clearance of free VEGF $Trap_{R1R2}$.

In all four cases, the luteal phase progesterone rise failed to occur at the anticipated time, and progesterone remained at follicular phase levels until after the first posttreatment ovulation, which occurred 32 ± 0.9 d after treatment, a significant delay, compared with control cycles ($P < 0.001$) in




FIG. 4. Serum profile of VEGF $Trap_{R1R2}$ in relation to inhibin B and estradiol after treatment with 0.25, 1, or 4 mg/kg given as a single, iv injection during the midfollicular phase. Note that in each group inhibin B and estradiol concentrations begin to recover after VEGF Trap values fall less than 1 mg/liter. Values are means ± SEM.

which ovulation occurred 3.4 ± 0.7 d after injection of vehicle or hFc (Fig. 7).

Comparison of mean hormonal data for late follicular phase control and treated cycles is shown in Fig. 7. Serum estradiol levels were significantly reduced, compared with pretreatment values ($P < 0.0001$) after administration of VEGF $Trap_{R1R2}$. Progesterone concentrations also were significantly suppressed ($P < 0.0001$) in the treated cycles relative to controls beyond d 6 (*i.e.* coincident with the luteal phase rise in progesterone in vehicle and Fc control cycles).

Similar to the observations after treatment in the midfollicular phase, three of the four treated animals exhibited vaginal bleeding during the first week, compared with one of five controls.

## Discussion

VEGF $Trap_{R1R2}$, administered at the mid- or late follicular phase, caused a rapid inhibition of estradiol and inhibin B secretion and blockade of ovulation in all 16 menstrual cycles evaluated, irrespective of dose. This demonstrates that VEGF is essential for the maintenance of normal ovarian function during the follicular phase in the macaque. The results were particularly remarkable with respect to the duration of the response observed after single injections of VEGF $Trap_{R1R2}$. The interval between treatment and recovery of ovarian function was clearly dose dependent, and the timing of functional recovery was very consistent within each dose group. Zimmermann *et al.* (9, 10) have shown that administration of antibodies to VEGF-R2 or VEGF beginning in the early or late follicular phase, respectively, also delay follicular development and ovulation in the rhesus monkey. However, in these studies, repeated antibody injections were required to achieve this effect, and the duration of suppression in ovarian function obtained was of shorter duration and more variable than observed after a single injection of the lowest dose of VEGF $Trap_{R1R2}$ studied, 0.25 mg/kg.




FIG. 5. Time to posttreatment ovulation in macaques treated with 0.25, 1, or 4 mg/kg VEGF $Trap_{R1R2}$ at the midfollicular phase or after 1 mg/kg at the late follicular phase.

The present findings in macaques confirm and extend our previous observations on effects of VEGF inhibition on ovarian structure and function in the marmoset, which focused on molecular and cellular changes (16, 17). In marmosets, VEGF inhibition throughout the follicular phase severely inhibits thecal angiogenesis and inhibits the growth of secondary follicles beyond the early antral stage (17). The inhibition of the normal, progressive increase in estradiol levels and blockade of ovulatory progesterone rises observed in the present study after single injections of the VEGF Trap in macaques are consistent with the anatomical changes observed in the marmoset ovary after Trap treatment. Somewhat surprisingly, macaques treated during the late follicular phase also exhibited a marked and persistent decline

**TABLE 1.** Peak preovulatory concentrations of estradiol and area under the curve for luteal progesterone in pre- and post treatment recovery cycles associated with treatment starting at the midfollicular (MF) or late follicular (LF) phase

| Stage | Dose (mg/kg) | Pre treatment | Post treatment | Significance |
|---|---|---|---|---|
| Peak estradiol (pmol/liter) | | | | |
| MF | 0.25 | 1034 ± 179 | 1629 ± 302 | NS |
| | 1 | 1545 ± 180 | 956 ± 259 | NS |
| | 4 | 1441 ± 425 | 1460 ± 552 | NS |
| LF | 1 | 1264 ± 527 | 739 ± 201 | NS |
| Luteal progesterone (nmol/liter) (area under the curve) | | | | |
| MF | 0.25 | 181 ± 47 | 184 ± 50 | NS |
| | 1 | 235 ± 46 | 227 ± 50 | NS |
| | 4 | 230 ± 54 | 191 ± 36 | NS |
| LF | 1 | 199 ± 12 | 199 ± 27 | NS |

Values are means ± SEM. NS, Not significant.

in estradiol levels. Because the dominant follicle has been selected by this time, this finding indicates that it too is susceptible to VEGF inhibition. Because much of the thecal vasculature of the preovulatory follicle has already been elaborated (23, 24), diminished vascular permeability may play a particularly significant role in the apparent ovulatory failure observed after VEGF inhibition in the late follicular phase. Taken together with the marmoset data, the above observations indicate that the inhibition of follicular maturation produced by administration of VEGF $Trap_{R1R2}$ is secondary to attenuation of the follicular vascular density and/or permeability, which in turn reduces the availability of growth factors, hormones, lipoproteins for steroid production, nutrients, and oxygen to the growing follicles.

The rapid and persistent rise in LH and FSH levels consistently observed after administration of the VEGF $Trap_{R1R2}$ is likely a direct consequence of the marked and abrupt attenuation of serum estradiol and inhibin B concentrations produced by VEGF inhibition. A similar scenario was described after administration of anti-VEGFR-2 in the rhesus monkey starting at the early follicular phase (10). This is the expected response to withdrawal of the negative feedback effect of the ovarian steroids and inhibin B on pituitary LH/FSH secretion. In the present study, the rise in gonadotrophin levels was most prompt when VEGF inhibition was initiated in the late follicular phase, perhaps reflecting increased sensitivity to withdrawal of negative feedback at this time. Irrespective of the timing of VEGF Trap administration, the magnitude of the FSH increase was relatively greater than that observed for LH and was similar in magnitude to that observed in the same species after specific inhibition of estradiol (20). However, the tonic elevation in pituitary gonadotrophin levels observed after administration of VEGF $Trap_{R1R2}$ was ineffective in promoting follicular development in the face of ongoing VEGF inhibition. Rather, restitution of follicular maturation, as evidenced by increasing serum estradiol and inhibin B levels, was evident only when circulating levels of free VEGF $Trap_{R1R2}$ fell less than 1 mg/liter. Similarly, administration of exogenous gonadotropins failed to stimulate ovarian follicular angiogenesis and growth in mice when endogenous VEGF signaling was inhibited by administration of antibodies against VEGFR-2 (11). These results, together with similar observations in the rhesus macaque, have led to the proposal that the access of FSH to the ovary is impeded when VEGF is inhibited (10). The rapid nature of the decline in inhibin B after inhibition of VEGF observed in the current study and VEGFR-2 in the early follicular phase (10) also suggests that the secretion of proteins from the developing follicle may also be impaired. The more gradual decline in serum estradiol could indicate that steroid secretion is less affected by the most immediate




FIG. 6. Serum concentrations of estradiol (*open circles*), progesterone (P4, *closed circles*) (*left panel*), FSH (*closed squares*) and LH (*open squares*) (*right panel*) in macaques injected in the late follicular phase with either Fc (1 mg/kg, iv) (control) or 1 mg/kg VEGF $Trap_{R1R2}$ iv (*arrow*). In the treated animal, note the suppression of estradiol, failure of ovulatory progesterone rises, and increases in LH and FSH, followed by recovery of normal pituitary-ovarian function.




FIG. 7. Serum concentrations of estradiol, progesterone, LH, and FSH after treatment with vehicle/Fc (control) or 1 mg/kg VEGF $Trap_{R1R2}$ in the late follicular phase. Values are means ± SEM, plotted with reference to the day of injection (d 0). Note timely rise in estradiol, followed by the preovulatory LH/FSH surge and the sustained rise in progesterone in controls. VEGF Trap administration results in the failure of the characteristic increases in estradiol and progesterone and the induction of a sustained increase in LH and FSH. Note the rapid rise in LH/FSH after treatment and the preferential increase in FSH, compared with the normal midcycle surge.

changes in the follicular vasculature produced by VEGF inhibition.

Once unbound VEGF $Trap_{R1R2}$ levels in the blood fell below efficacious concentrations, normal ovarian function was rapidly restored in all cases. The time required for the recovery of follicular activity was dose dependent, but remarkably consistent within doses, and was followed within 2 wk by ovulation such that the first posttreatment ovulations occurred on average 23, 30, and 43 d after injection of 0.25, 1, or 4 mg/kg of VEGF Trap $_{R1R2}$, respectively. Once reestablished, posttreatment ovarian cycles were comprised of characteristic follicular and luteal phases of normal length, and hormonal measurements confirmed that the magnitude as well as duration of follicular estradiol and luteal progesterone secretion was not significantly different between pre- and posttreatment cycles. Thus, there was no evidence of a deleterious effect of transient VEGF inhibition on subsequent ovarian cycles. Immature follicles are not likely to be adversely influenced by transient VEGF inhibition, or the resultant increases in serum LH/FSH levels, because little or no angiogenesis is taking place in the theca of small follicles, and their growth and survival is thought to be gonadotropin independent at this stage (24, 25). However, longer-term effects of VEGF inhibition on pituitary-ovarian function cannot be excluded, particularly in the context of chronic treatment.

Intravenous administration of VEGF $Trap_{R1R2}$ was well tolerated in all cases. Only one macaque produced antibodies to the protein on repeated treatment. This animal had initially received a dose of 12.5 mg/kg. After a second injection of 4 mg/kg, the posttreatment recovery of ovarian function occurred earlier than usual, coincident with a sudden decline in serum levels of free Trap due to the development of antibodies. There was no evidence of concomitant morbidity, and further observation confirmed that there was no appreciable effect on subsequent ovulatory cycles.

An increased incidence of vaginal bleeding was observed during the first week of treatment in all VEGF Trap-treated groups, presumably reflecting the response of the endometrium to suppression of ovarian steroids. Possible direct effects of inhibition of VEGF at the endometrial level have yet to be determined in a menstruating species.

The development of effective inhibitors of angiogenesis, and in particular those that block the actions of VEGF, may open new avenues for the treatment of reproductive disorders characterized by pathological angiogenesis, inflammation, and increased vascular permeability. For example, polycystic ovarian syndrome (PCOS) is characterized by the formation of multiple follicular cysts in which the theca is hyperplastic and hypervascularized and stromal blood flow is increased (26, 27). We elected to study the effects of VEGF inhibition at the midfollicular phase because it is this stage of the cycle that normal follicular size and estradiol production are closest to that observed in the ovaries of women with PCOS. In the normal cycle, administration of the VEGF $Trap_{R1R2}$ blocks the expected progressive rise in estradiol that ordinarily occurs in the second half of the follicular phase, indicating that VEGF inhibition induces atresia of the recruited follicles at the antral stage of development. Thus, short-term administration of VEGF inhibitors to women with PCOS may cause atresia of accumulated antral follicles and also reduce ovarian vascular permeability, thereby producing benefits similar to those currently derived from ovarian cauterization (28).

Antiangiogenic therapies, particularly those that target VEGF signaling, also have potential applications to other reproductive disorders. For example, ovarian hyperstimulation syndrome (OHSS) is an infrequent but severe complication of the hormonal regimen used to induce follicular growth for *in vitro* fertilization (12, 29, 30). It is characterized by massive follicular growth and luteinization, associated with a dramatic and global increase in vascular permeability. VEGF is thought to play an important role in the pathogenesis of OHSS (29, 30), and its inhibition may be a valuable therapeutic option (12). Administration of antiangiogenic agents may also find applications in reproductive medicine beyond syndromes characterized by a primary ovarian pathology. For example, uterine conditions, such as endometriosis, fibroids, and menorrhagia, are influenced by ovarian steroids and also involve an angiogenic component. In these situations, administration of an antiangiogenic agent could have dual benefits, as a consequence of reduction in ovarian steroids coupled with a direct antiangiogenic effect at the pathological site.

In conclusion, it has been demonstrated that a single injection of VEGF Trap in the mid- or late follicular phase in

the macaque produces a prolonged, dose-related suppression of ovarian function. These results suggest that VEGF Trap affords the opportunity for development of novel treatments for some types of ovarian dysfunction and infertility, particularly those conditions characterized by pathological angiogenesis and excessive vascular permeability, such as PCOS, OHSS, and endometriosis.

## Acknowledgments

We thank Keith Morris, Irene Grieg, Mark Fisken, and James MacDonald for animal care; Ian Swanston, Jane Hacket, George Johnstone, and Fiona Pitt for hormone assays; and Ted Pinner for graphics. H.M.F. is grateful to Dr. R. A. Anderson, Dr. W. C. Duncan, Professor A. S. McNeilly, and Dr. C. Wulff for valuable discussions.

Received August 10, 2004. Accepted November 11, 2004.

Address all correspondence and requests for reprints to: Hamish M. Fraser, Ph.D., D.Sc., MRC Human Reproductive Sciences Unit, The University of Edinburgh Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB, United Kingdom. E-mail: h.fraser@hrsu.mrc.ac.uk.

## References

1. **Hazzard TM, Stouffer RL** 2000 Angiogenesis in ovarian follicular and luteal development. Baillieres Best Pract Res Clin Obstet Gynaecol 14:883–900
2. **Findlay JK** 1986 Angiogenesis in reproductive tissues. J Endocrinol 111:357–366
3. **Folkman J** 1992 Angiogenesis in female reproductive organs. In: Alexander NJ, D'Arcangues C, eds. Steroid hormones and uterine bleeding. Washington, DC: AAAS Press; 143–158
4. **Reynolds LP, Killilea SD, Redmer DA** 1992 Angiogenesis in the female reproductive system. FASEB J 6:886–892
5. **Klauber N, Rohan RM, Flynn E, D'Amato RJ** 1997 Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med 3:443–446
6. **Fraser HM, Dickson SE, Morris KD, Erickson GF, Lunn SF** 1999 The effects of the angiogenesis inhibitor TNP-470 on luteal establishment and function in the primate. Hum Reprod 14:2054–2060
7. **Hazzard TM, Rohan RM, Molskness TA, Fanton JW, D'Amato RJ, Stouffer RL** 2002 Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function. Endocrine 17:199–206
8. **Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA, Bicknell R** 2000 Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141:995–1000
9. **Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J, Ferin, M** 2001 Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J Clin Endocrinol Metab 86:768–772
10. **Zimmermann RC, Xiao E, Bohlen P, Ferin M** 2002 Administration of anti-vascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. Endocrinology 143:2496–2502
11. **Zimmermann RC, Hartman T, Kavic S, Pauli S A, Bohlen P, Sauer MV, Kitajewski J** 2003 Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. J Clin Invest 112:659–669
12. **Gomez R, Simon C, Remohi J, Pellicer A** 2002 Vascular endothelial growth factor receptor 2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology 143: 4339–4348
13. **Ferrara N, Chen H, Davis-Smyth T, Geber H-P, Nguyen T-N, Peers D, Chisholm V, Hillan KJ, Schwall RH** 1998 Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4:336–340
14. **Hazzard TM, Xu F, Stouffer RL** 2002 Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol Reprod 67:1305–1312
15. **Wulff C, Wilson H, Rudge JS, Wiegand SJ, Lunn SF, Fraser HM** 2001 Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap A40. J Clin Endocrinol Metab 86:3377–3386
16. **Wulff C, Wiegand SJ, Saunders PTK, Scobie GA, Fraser HM** 2001 Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1Fc (vascular endothelial growth factor trapA40). Endocrinology 142:3244–3254
17. **Wulff C, Wilson H, Wiegand SJ, Rudge JS, Fraser HM** 2002 Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor trap R1R2. Endocrinology 143:2797–2807
18. **Fraser HM, Sandow J, Seidel H, Von Rechenberg W** 1987 An implant of a gonadotropin releasing hormone agonist (buserelin) which suppresses ovarian function in the macaque for 3–5 months. Acta Endocrinol (Copenh) 115:521–527
19. **Fraser HM, Sandow J, Cowen GM, Lumsden MA, Haining R, Smith SK** 1990 Long-term suppression of ovarian function by a luteinizing hormone releasing hormone agonist implant in patients with endometriosis. Fertil Steril 53:61–68
20. **Fraser HM, Groome NP, McNeilly AS** 1999 Follicle stimulating hormone-inhibin B interactions during the follicular phase of the primate menstrual cycle revealed by GnRH antagonist and anti-estrogen treatment. J Clin Endocrinol Metab 84:1365–1369
21. **Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS** 2002 VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393–11398
22. **Fraser HM, Sandow J** 1985 Suppression of follicular maturation by infusion of a luteinizing hormone-releasing hormone agonist starting during the late luteal phase in the stump-tailed macaque monkey. J Clin Endocrinol Metab 60:579–584
23. **Suzuki T, Sasano H, TaKaya R, Fukaya T, Yajima A, Nagura H** 1998 Cyclic changes of vasculature and vascular phenotypes in normal human ovaries. Hum Reprod 13:953–959
24. **Taylor PD, Hillier SG, Fraser HM,** 2004 Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol 183:1–17
25. **McGee EA, Hsueh AJW** 2000 Initial and cyclic recruitment of ovarian follicles. Endocr Rev 21:200–214
26. **Abbott DH, Dumesic DA, Franks S** 2002 Developmental origin of polycystic ovary syndrome—a hypothesis. J Endocrinol 174:1–5
27. **Pan HA, Wu MH, Cheng YC, Li CH, Chang FM** 2002 Quantification of Doppler signal in polycystic ovary syndrome using three-dimensional power Doppler ultrasonography: a possible new marker for diagnosis. Hum Reprod 17:201–206
28. **Paranezhad ME, Bagheri H, Alborzi S, Schmidt EH** 2003 Ovarian stromal blood flow changes after laparoscopic ovarian cauterisation in women with polycystic ovary syndrome. Hum Reprod 18:1432–1437
29. **McIlhinney B, McClure N** 1999 Ovarian hyperstimulation syndrome. Baillieres Best Pract Res Clin Obstet Gynaecol 14:103–122
30. **Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK** 2002 Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 87:3300–3308

**JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the endocrine community.**